Table 4 Univariate and multivariate analyses for PFS of ovarian cancer
Univariate analysis | |||
|---|---|---|---|
Variable | n (%) | Median (months) | p value |
Age: | |||
<70 | 118 (94.4 %) | 10.4 | 0.51 |
≥70 | 7 (5.6 %) | 16.0 | |
Performance status WHO: | |||
▪ 0 | 19 (15.2 %) | 14.7 | 0.06 |
▪ Other | 106 (84.8) | 21.4 | |
FIGO stage: | |||
▪ Early (I,II) | 24 (19.2 %) | NR | < 0.001 |
▪ Advanced (III, IV) | 101 (80.8 %) | 13.4 | |
Chemotherapy regimen: | |||
▪ With paclitaxel | 113 (90.4 %) | 16.8 | 0.032 |
▪ Without paclitaxel | 12 (9.6 %) | 10.3 | |
Chemotherapy regimen: | |||
▪ With cisplatin | 55 (44.0 %) | 23.0 | 0.24 |
▪ With carboplatin | 70 (56.0 %) | 13.5 | |
Type of histology: | |||
▪ Serous | 68 (54.4 %) | 13.2 | < 0.001 |
▪ Other | 57 (45.6 %) | 34.8 | |
Grading: | |||
▪ 1 and 2 | 45 (36.0 %) | 16.0 | 0.40 |
▪ 3 and unspecified | 80 (64.0 %) | 14.6 | |
Primary surgery: | |||
▪ Optimal (<1 cm) | 77 (61.6 %) | 24.7 | < 0.001 |
▪ Suboptimal (>1 cm) | 48 (38.4 %) | 11.0 | |
BRCA1 status: | |||
▪ Wild type | 108 (86.4 %) | 14.6 | 0.58 |
▪ Germline mutation | 17 (13.6 %) | 21.5 | |
Multivariate analysis | |||
Variable | HR (95 % CI) | p value | |
FIGO stage: | |||
▪ Early (I,II) | 0.21 (0.071 – 0.634) | 0.006 | |
▪ Advanced (III, IV) | |||
Chemotherapy regimen: | |||
▪ With paclitaxel | 0.46 (0.242 – 1.020) | 0.034 | |
▪ Without paclitaxel | |||
Type of histology: | |||
▪ Serous | 0.55 (0.318 – 0.916) | 0.027 | |
▪ Other | |||
Primary surgery: | |||
▪ Optimal (<1 cm) | 0.54 (0.308 – 0.804) | 0.011 | |
▪ Suboptimal (>1 cm) | |||
BRCA1 status: | NG | NS | |
▪ Wild type | |||
▪ Germline mutation | |||